# Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial

> **NCT03739853** · PHASE4 · COMPLETED · sponsor: **University of Oxford** · enrollment: 192 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Sulfasalazine
- **DRUG:** Leflunomide
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT03739853
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-14
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739853, "Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03739853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*